Diagnosis of diabetic kidney disease: state of the art and future perspective

Kidney International Supplements

Volumn 8, Issue 1, 2018, Pages 2-7

  Persson, Frederik ^a   Rossing, Peter ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

albuminuria; biomarker; diabetic kidney disease; diabetic nephropathy; glomerular filtration rate

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE;

ARTERIAL PRESSURE; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; END STAGE RENAL DISEASE; GENETICS; GENOMICS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; METABOLOMICS; MICROALBUMINURIA; MORBIDITY; MORTALITY; NONHUMAN; PATHOLOGY; PATIENT CARE; PATIENT MONITORING; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PROTEOMICS; REVIEW; RISK; TRANSCRIPTOMICS; URINARY EXCRETION; URINE SAMPLING;

EID: 85039867196     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1016/j.kisu.2017.10.003     Document Type: Review

References (50)

1. Afkarian, M., Zelnick, L.R., Hall, Y.N., et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316 (2016), 602–610.
2. Borch-Johnsen, K., The prognosis of insulin-dependent diabetes mellitus. An epidemiological approach. Dan Med Bull 39 (1989), 336–349.
3. de Boer, I.H., Gao, X., Cleary, P.A., et al. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC Study. Clin J Am Soc Nephrol 11 (2016), 1969–1977.
4. Gall, M.-A., Rossing, P., Skøtt, P., et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34 (1991), 655–661.
5. Tuttle, K.R., Bakris, G.L., Bilous, R.W., et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 37 (2014), 2864–2883.
6. Andresdottir, G., Jensen, M.L., Carstensen, B., et al. Improved prognosis of diabetic nephropathy in type 1 diabetes. Kidney Int 87 (2015), 417–426.
7. Andresdottir, G., Jensen, M.L., Carstensen, B., et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 37 (2014), 1660–1667.
8. Parving, H.H., Mauer, M., Fioretto, P., et al. Diabetic nephropathy. Brenner, B., (eds.) Brenner and Rector's The Kidney, Vol. 1, 2012, Elsevier, Philadelphia, PA, 1411–1454.
9. American Diabetes Association. Microvascular Complications and Foot Care. Diabetes Care 40 (2017), S88–S98.
10. Perkins, B.A., Ficociello, L.H., Silva, K.H., et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348 (2003), 2285–2293.
11. Hovind, P., Tarnow, L., Rossing, P., et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Br Med J, 328, 2004, 1105.
12. Gaede, P., Tarnow, L., Vedel, P., et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19 (2004), 2784–2788.
13. Solini, A., Penno, G., Bonora, E., et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care 35 (2012), 143–149.
14. Thorn, L.M., Gordin, D., Harjutsalo, V., et al. The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes. Diabetes Care 38 (2015), 2128–2133.
15. Kidney Disease: Improving Global Outcomes Group (KDIGO) Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
16. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 Update. Am J Kidney Dis 60 (2012), 850–886.
17. Parving, H.H., Lewis, J.B., Ravid, M., et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69 (2006), 2057–2063.
18. Lambers Heerspink, H.J., Gansevoort, R.T., Brenner, B.M., et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 21 (2010), 1355–1360.
19. Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
20. Jorgensen, M.E., Kristensen, J.K., Reventlov Husted, G., et al. The Danish Adult Diabetes Registry. Clin Epidemiol 8 (2016), 429–434.
21. Hellemons, M.E., Denig, P., de Zeeuw, D., et al. Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. Nephrol Dial Transplant 28 (2013), 706–715.
22. Levey, A.S., de Jong, P.E., Coresh, J., et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80 (2011), 17–28.
23. Araki, S., Haneda, M., Koya, D., et al. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36 (2013), 1248–1253.
24. Nielsen, S.E., Sugaya, T., Hovind, P., et al. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33 (2010), 1320–1324.
25. Nguyen, T.Q., Tarnow, L., Jorsal, A., et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31 (2008), 1177–1182.
26. Astrup, A.S., Tarnow, L., Pietraszek, L., et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 31 (2008), 1170–1176.
27. Sharma, K., Karl, B., Mathew, A.V., et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 24 (2013), 1901–1912.
28. Stenvinkel, P., Carrero, J.J., Axelsson, J., et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 3 (2008), 505–521.
29. Niewczas, M.A., Gohda, T., Skupien, J., et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23 (2012), 507–515.
30. Forsblom, C., Moran, J., Harjutsalo, V., et al. Added value of soluble tumor necrosis factor alpha receptor-1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care 37 (2014), 2334–2342.
31. Gohda, T., Niewczas, M.A., Ficociello, L.H., et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23 (2012), 516–524.
32. Krolewski, A.S., Skupien, J., Rossing, P., et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int 91 (2017), 1300–1311.
33. Mischak, H., Ioannidis, J.P., Argiles, A., et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 42 (2012), 1027–1036.
34. Looker, H.C., Colombo, M., Hess, S., et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int 88 (2015), 888–896.
35. Parving, H.H., de Zeeuw, D., Cooper, M.E., et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 19 (2008), 771–779.
36. Germain, M., Pezzolesi, M.G., Sandholm, N., et al. SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. Diabetologia 58 (2015), 543–548.
37. Sandholm, N., Salem, R.M., McKnight, A.J., et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet, 8, 2012, e1002921.
38. Sandholm, N., Van Zuydam, N., Ahlqvist, E., et al. The genetic landscape of renal complications in type 1 diabetes. J Am Soc Nephrol 28 (2017), 557–574.
39. Kottgen, A., Pattaro, C., Boger, C.A., et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 42 (2010), 376–384.
40. Komorowsky, C.V., Brosius, F.C. III, Pennathur, S., et al. Perspectives on systems biology applications in diabetic kidney disease. J Cardiovasc Transl Res 5 (2012), 491–508.
41. Brosius, F.C., Tuttle, K.R., Kretzler, M., JAK inhibition in the treatment of diabetic kidney disease. Diabetologia 59 (2016), 1624–1627.
42. Pena, M.J., Lambers Heerspink, H.J., Hellemons, M.E., et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet Med 31 (2014), 1138–1147.
43. Solini, A., Manca, M.L., Penno, G., et al. Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics. J Clin Endocrinol Metab 101 (2016), 696–704.
44. Niewczas, M.A., Sirich, T.L., Mathew, A.V., et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 85 (2014), 1214–1224.
45. Good, D.M., Zurbig, P., Argiles, A., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9 (2010), 2424–2437.
46. Zurbig, P., Jerums, G., Hovind, P., et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61 (2012), 3304–3313.
47. Roscioni, S.S., de Zeeuw, D., Hellemons, M.E., et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 56 (2013), 259–267.
48. Schanstra, J.P., Zurbig, P., Alkhalaf, A., et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol 26 (2015), 1999–2010.
49. Lindhardt M, Persson F, Zurbig P, et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study [e-pub ahead of print]. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfw292.
50. Siwy J, Zurbig P, Argiles A, et al. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis [e-pub ahead of print]. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfw337.